BioPharma Dive - Latest News

Mirum drug for rare genetic disease gains FDA approval

Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendinous xanthomatosis, in a 2023 deal with Travere Therapeutics.

Feb 24, 2025 - 18:35
 0
Mirum drug for rare genetic disease gains FDA approval

Mirum gained the drug, which it will sell as Ctexli for adults with cerebrotendinous xanthomatosis, in a 2023 deal with Travere Therapeutics.

Read More

Tags:

Previous Article

The Rise And Fall Of Studebaker: What Went Wrong?

Next Article

Summit partners with Pfizer to study bispecific, ADC combinations

Related Posts

Bristol Myers gives first peek at closely watched launch of schizophrenia drug

Bristol Myers gives first peek at closely watched launc...

Feb 9, 2025  0

Bayer braces for ‘difficult’ year before turnaround pays dividends

Bayer braces for ‘difficult’ year before turnaround pay...

Mar 5, 2025  0

Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer

Pfizer names Patrizia Cavazzoni, former top FDA officia...

Feb 24, 2025  0